Puma Biotechnology | PBYI - Debt


Puma Biotechnology reported $89.06M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Exelixis USD 169.54M 3.5M Mar/2026
Gilead Sciences USD 24.94B 5M Dec/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 39.43M 982K Mar/2026
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 1.31B 571M Dec/2025
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Takeda JPY 4.85T 208B Dec/2025
TG Therapeutics USD 253.71M 8.37M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026